Hong Kong Household Products Stock News

SEHK:6938
SEHK:6938Biotechs

Suzhou Ribo Life Science (SEHK:6938) Valuation Check After Recent Share Price Weakness

Why Suzhou Ribo Life Science Is Drawing Investor Attention Suzhou Ribo Life Science (SEHK:6938) has come onto investors’ radar after a month return of about 8% decline, extending a weaker year to date performance and raising fresh questions about sentiment toward its small nucleic acid drug pipeline. See our latest analysis for Suzhou Ribo Life Science. The latest 1 day share price return of a 5.40% decline, on a last close of HK$70.05, sits against a 7 day share price return of 1.08% and a...
SEHK:23
SEHK:23Banks

Bank Of East Asia SEHK 23 Margin Compression Challenges Bullish Earnings Growth Narrative

Bank of East Asia (SEHK:23) has just posted its FY 2025 first half results, with total revenue of HK$7.7b and basic EPS of HK$0.86, alongside net income of HK$2.3b. The bank reported revenue of HK$7.5b and EPS of HK$0.69 in the first half of 2024, followed by revenue of HK$7.9b and EPS of HK$0.84 in the second half of 2024. As a result, FY 2025 starts after three consecutive reported periods of higher earnings per share. With that backdrop, investors are likely to focus on how its net...
SEHK:2252
SEHK:2252Medical Equipment

Shanghai MicroPort MedBot (SEHK:2252) Valuation After Global Toumai Robot Orders And Remote Surgery Progress

Shanghai MicroPort MedBot (Group) (SEHK:2252) is back on investors’ radar after reporting more than 200 commercial orders for its Toumai laparoscopic surgical robot, with around 130 systems installed across nearly 50 countries and regions. See our latest analysis for Shanghai MicroPort MedBot (Group). The recent Toumai order momentum and remote surgery progress come as the shares trade at HK$29.0, with an 11.71% 1 day share price return and 22.99% 90 day share price return, alongside a 50.57%...
SEHK:3738
SEHK:3738Software

Vobile Group (SEHK:3738) Valuation Check After Finloop IP Tokenization Collaboration

Vobile Group (SEHK:3738) has drawn fresh attention after announcing a collaboration with Finloop Finance Technology to tokenize offshore real world assets tied to cultural and creative intellectual property, with the aim of building a compliant IP backed digital asset ecosystem. See our latest analysis for Vobile Group. The Finloop agreement lands at a time when momentum in Vobile Group’s shares has been picking up, with a 7 day share price return of 37.09% and a year to date share price...
SEHK:799
SEHK:799Entertainment

Discover 3 Asian Penny Stocks With Market Caps Over US$900M

As global markets navigate a mixed landscape marked by volatility and shifts in investor sentiment, Asia's stock markets continue to capture attention with their unique opportunities. Penny stocks, though often viewed as speculative, can offer intriguing possibilities for growth, particularly when they are supported by strong financial health and solid fundamentals. In this article, we explore three Asian penny stocks that stand out for their potential to deliver impressive returns while...
SEHK:1286
SEHK:1286Machinery

Undiscovered Gems in Asia to Explore This February 2026

As global markets navigate a mix of economic signals, with small-cap and value-oriented stocks gaining traction amidst concerns over artificial intelligence investments, Asia's market landscape presents unique opportunities for investors seeking potential growth. In this dynamic environment, identifying promising stocks often involves looking for companies that can capitalize on regional trends and demonstrate resilience in the face of broader market volatility.
SEHK:6855
SEHK:6855Biotechs

Ascentage China IND Clearance Puts BTK Degrader On Global Cancer Track

Ascentage Pharma Group International (SEHK:6855) received investigational new drug clearance in China for APG-3288, its next generation BTK targeted protein degrader. The Chinese clearance follows earlier U.S. FDA approval for clinical testing, aligning the program across two major drug development markets. APG-3288 is being developed for treatment resistant blood cancers, with a focus on hematologic malignancies that do not respond to existing BTK therapies. For investors tracking oncology...